
2026 Lipid Guidelines Use PREVENT Scores to Tailor Therapy
The 2026 American dyslipidemia guideline endorses PREVENT-ASCVD risk equations to guide primary prevention therapy and suggests considering lipid-lowering treatment for adults at intermediate risk based on a 10-year PREVENT-ASCVD risk, with additional considerations for borderline risk and for patients with moderate subclinical atherosclerosis, aiming to lower LDL cholesterol.






